Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06013423)

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases: a one-minute explainerNCT060134231 min

Biospecimen Collection trial for Acute Leukemia of Ambiguous Lineage (NCT06013423). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients aged six months–65 years with selected high-risk leukemias, MDS/MPN, lymphoma or BPDCN. Disease-specific remission and blast-count rules apply.

The idea: chemotherapy and total-body radiation prepare the body for donor cord-blood cells to rebuild blood production. Both regimens use fludarabine/cyclophosphamide; one adds thiotepa. The high-dose radiation arm ends at age 30. Cyclosporine and mycophenolate help limit donor-cell attacks on healthy tissue.

This phase 2 study plans 54 patients. Ann Dahlberg leads at Fred Hutch/University of Washington in Seattle, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.